Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017

May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced...

FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017

Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be stopped in the...

Study Reveals Low Adoption of IAEA Recommendations for Reduced Nuclear Cardiology Radiation Exposure
News | Radiation Dose Management | May 12, 2017

A study in 65 countries has revealed low adoption of International Atomic Energy Agency (IAEA) recommendations to...

Large Nuclear Cardiology Laboratory Slashes Radiation Dose 60 Percent in Eight Years
News | Radiation Dose Management | May 11, 2017

A large nuclear cardiology laboratory in Missouri has slashed its average radiation dose by 60 percent in eight...

low-dose lung CT scan

An example of a low-dose CT scan of the lungs, showing lung cancer. Image courtesy of Toshiba.

Feature | Lung Cancer | May 05, 2017 | Alison Grimes

The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging.

PET/CT

The Philips Ingenuity TF PET/CT system leverages multiple technologies.

Feature | Radiation Oncology | May 05, 2017 | By Lola Koktysh

The continuum of personalized care, covering individualized prevention and therapy, translates into multiple changes...

Videos | Business | May 03, 2017

Kim A.

PET/CT Helps Predict Therapy Effectiveness in Pediatric Brain Tumors

FIGURE: MRI AND PET-MRI FUSION IMAGES OF PATIENTS WITH DIPG. Top row: Zr-89-bevacizumab PET (144 hrs p.i.) fused with T1-Gd weighted MRI per patient; middle row: T1-Gd weighted MRI; lower row: T2-weighted/FLAIR MR-images. Five tumors show variable uptake of Zr-89-bevacizumab (white arrows), with both PET negative and positive areas within each tumor. Two primary tumors are completely PET negative (Fig. 1C and 1E), while the T2 weighted images show tumor infiltration in the whole pons of both patients. In the middle row, the red arrows represent the areas of contrast enhancement within the tumor. In four out of five primary tumors, the PET-positive area corresponds with the contrast-enhancing area on MRI of the tumors (Fig. 1A, 1B, 1F and 1G). In Fig. 1C, the tumor shows an MRI contrast-enhancing area, while there is no Zr-89-bevacizumab uptake. Fig. 1D shows a PET positive tumor, while no Gd-enhancement is observed on MRI. Credit: Sophie Veldhuijzen van Zanten and Marc Jansen, VU University Medical Center, Amsterdam, The Netherlands.

News | PET-CT | May 02, 2017

In a first-ever molecular drug-imaging study in children, researchers in The Netherlands used whole-body positron...

Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017

April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the...

Videos | Nuclear Imaging | April 28, 2017

David Wolinsky, M.D., director of nuclear cardiology at Cleveland Clinic Florida and past-president of the American...

News | Prostate Cancer | April 24, 2017

April 24, 2017 — Cancer Targeted Technology recently announced it is focusing on small molecules that target pivotal...

SPECT/CT Imaging Test Shown Accurate in Ruling Out Kidney Cancers
News | SPECT Imaging | April 24, 2017

The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely...

University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017

The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...

IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017

IBA Molecular announced that it has merged with previous acquisition Mallinckrodt Nuclear Medicine LLC to form the...

PET
Feature | Imaging | April 11, 2017 | By Greg Freiherr
FDG-PET, cell mutations, lung cancer patients, non-small cell lung cancer, NSCLC, Journal of Nuclear Medicine study

From left to right are patients with EGFR mutation, KRAS mutation, and EGFR– and KRAS– tumors, respectively. Stage I and III tumors are shown in the top and bottom rows, respectively. Arrows indicate the locations of the lung tumors. Credit: Stephen S.F. Yip, Ph.D., and Hugo Aerts, Ph.D., Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston; John Kim, M.D., University of Michigan Health System, Ann Arbor, Mich.

News | PET Imaging | April 05, 2017

Researchers have used positron emission tomography (PET) to successfully identify genetic cell mutations that can...

GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017

GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered in Nashville,...

Gamma Medica, LumaGEM molecular breast imaging system, MBI, Mercy Medical Center, Long Island, first New York install
News | Breast Imaging | April 04, 2017

Gamma Medica announced in late March that Mercy Medical Center, a member of Catholic Health Services of Long Island...

Northwestern Memorial Hospital, MR-PET scanner, first in Illinois, Siemens Biograph mMR
News | PET-MRI | March 31, 2017

Northwestern Memorial Hospital is now home to the Chicago area's first combined magnetic resonance (MRI) and...

News | Radiopharmaceuticals and Tracers | March 29, 2017

Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate) has been included...

Overlay Init